One Step Closer in the Global Fight Against Respiratory Syncytial Virus (RSV)September 9, 2022
For more than five years, Pfizer has been advancing a novel vaccine candidate for respiratory syncytial virus (RSV), a common and pervasive cause of acute respiratory illness. The virus can affect the lungs and breathing passages of an infected individual and can be potentially life-threatening for young infants, the immunocompromised, and older adults.
The company recently announced topline results from its late-stage clinical trial for adults 60 years of age or older. The bivalent vaccine candidate, known as RSVpreF, comprises two proteins chosen to optimize protection against RSV and is being studied in clinical trials for both adults through direct vaccination and infants through maternal immunization.
Based on the results for adults 60 years of age or older, Pfizer plans to seek regulatory approval from the U.S. Food and Drug Administration for this population this fall. If approved by the FDA, RSVpreF has the potential to be the first bivalent vaccine candidate to help protect adults 60 years of age or older from RSV.
A separate Phase 3 trial of the RSVpreF vaccine candidate in pregnant individuals to help protect their infants from RSV in the first few months of life remains ongoing. The results from the study are anticipated to read out later this year.
Helping to Protect Vulnerable Populations
Around the world, there is an urgent need for innovative medicines and vaccines that can help treat and prevent RSV.
While scientists and researchers have worked to develop RSV vaccines for over half a century, there is no currently approved vaccine for RSV and treatment options are limited and focus mainly on supportive care for those with the illness. Pfizer is rising to the challenge of developing potential innovations as it represents an opportunity to apply its infectious disease R&D expertise with purpose.
Commitment to RSV
Similar to its approach in helping address COVID-19, Pfizer is also seeking to potentially bring forth treatment options to support those who become infected from RSV in addition to developing a vaccine to help prevent illness in infants and older adults.
Pfizer’s portfolio of promising therapeutic candidates, resulting from the acquisition of ReViral, has the potential, if clinically successful and approved, to help change the standard of care for those with RSV disease.
This is an exciting time in infectious disease R&D, as scientific discoveries and technological breakthroughs are paving the way for novel vaccines and medicines. Today, Pfizer is one step closer to potentially helping address the substantial burden of RSV disease.
Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.